Generic Name and Formulations:
Gadoversetamide 330.9mg/mL; soln for IV inj; preservative-free.
Indications for OPTIMARK:
For use with magnetic resonance imaging (MRI) in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues. For use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.
Give as bolus peripheral IV injection at a dose of 0.2mL/kg at a rate of 1–2mL/sec.
Chronic, severe renal disease (GFR <30mL/min/1.73m2) or acute renal injury.
Increase risk for nephrogenic systemic fibrosis in patients with impaired elimination of gadolinium-based contrast agents. Screen for acute kidney injury and other conditions that reduce renal function. Use lowest possible dose. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. Sickle cell anemia and other hemoglobinopathies. Hemolytic anemias. History of asthma, allergy or other respiratory disorders. Anaphylactoid reactions possible; have emergency resuscitative equipment available. Monitor for hypersensitivity during and for several hours after injection; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers: not recommended; discard breast milk up to 72hrs after injection.
Interference in serum iron, copper, zinc, and calcium measurements.
Gadolinium-based contrast agent.
Headache, vasodilation, taste perversion, dizziness, nausea, paresthesia; anaphylaxis (may be fatal).
Vials (5mL, 10mL, 15mL, 20mL)—10; Syringes (10mL, 15mL, 20mL, 30mL)—10